FDA Approves Coagulation Factor VIIa (Recombinant)-jncw for Hemophilia
The FDA has approved coagulation factor VIIa (recombinant)-jncw to control bleeding in patients aged 12 years and older with hemophilia A or B with...
High Bleeding Events in SCD Warrant Consideration of In-Hospital Ulcer Prophylaxis
By the time they reach age 40, 21% of patients with sickle cell disease (SCD) will have experienced a bleeding event, with most events...
Higher Altitudes, Higher Hemoglobin: Mapping Switzerland’s Topography and Hemoglobin Levels
Even small increases in residential altitude significantly elevated blood hemoglobin (Hb) and ferritin levels in young men living in Switzerland, according to a study...
Hemophilia A Gene Therapy Offers Sustained Clinical Benefit
In men with severe hemophilia A, treatment with an adeno-associated virus serotype 5 (AAV5) vector containing a B-domain-deleted factor VIII (FVIII) gene, known as...
Novo Nordisk Halts Concizumab Trials After Thrombotic Events
After observing blood clots in some patients enrolled in clinical trials of concizumab, Novo Nordisk has paused one mid-stage and two late-stage studies of...
BioMarin Sets High Price Tag for Hemophilia Gene Therapy Candidate
If its experimental gene therapy for patients with hemophilia A is approved by the FDA, BioMarin Pharmaceutical is considering pricing valoctocogene roxaparvovec (valrox) between...
How Common Is Serotonin Release Assay-Negative Heparin-Induced Thrombocytopenia?
Heparin-induced thrombocytopenia (HIT), a prothrombotic drug reaction caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies, is commonly diagnosed with the platelet serotonin-release assay (SRA)...
Evaluating Efgartigimod in Patients With Primary Immune Thrombocytopenia
Treatment with the neonatal Fc receptor antagonist efgartigimod led to clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according...
FLT180a Shows Efficacy in Hemophilia B at High Doses
When administered at a high dose, the experimental gene therapy FLT180a restored activity of clotting factor IX (FIX) within normal ranges in men with...
ER-Based Protocol Improves the Accuracy of von Willebrand Disease Testing in Young Patients With...
Watch our interview with Megan C. Brown, MD.
Researchers at Children’s Healthcare of Atlanta (CHOA) have developed an emergency department (ED)–based protocol that helps standardize...
Current Issue
July 2020 Volume 6 Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
